Wed, Jul 23, 2014, 9:39 AM EDT - U.S. Markets close in 6 hrs 21 mins

Recent

% | $
Click the to save as a favorite.

Novadaq Technologies Inc. Message Board

  • e11ndofwar e11ndofwar Dec 19, 2013 10:38 AM Flag

    Just a thought

    What we know.
    Originally, the full results of the Pilar study were going to be presented at a medical convention during the 4th quarter of this year. That was subsequently changed after the results were in to publish in a major medical journal.
    What we know.
    The results of the preliminary study revealed zero negative events post operation.
    What we know.
    At a CC, Arun was questioned about the success of the full study. He responded by simply saying, do the math. The first half of the study had zero negative events, so even if the 2nd half had the normal number of events, the total number would be substantially below the norm.
    At the Investor Day conference during the panel discussion, one of the doctors indicated that the pilar results could create a real dilemna for the governing bodies related to standard of care. Would they require a time consuming phase III trial if the Pilar results were outstanding. What if there were zero events totally? Given the first half results this is well within the realm of possibilty.

    For myself, I am anxiously counting the days until that report is published. They have to be truly outstanding. Afterall, why else would Arun walk away from the convention presentation?
    regards endo

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
NVDQ
16.90+0.20(+1.20%)9:39 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.